Pulmonary delivery of 17-hydroxyprogesterone caproate (17-HPC)

Abstract

The invention relates to 17-HPC pulmonary formulations for administration by inhalation comprising 17-HPC and a pharmaceutically acceptable excipient. Particle size reduction of 17-HPC is required for the pulmonary delivery, and can be achieved with a surfactant or water without the surfactant. Preferred pulmonary formulations include a powder blend comprising a therapeutically effective amount of at least one steroid hormone (progestogen) as a glucocorticoid sensitizer, and at least one pharmaceutically acceptable excipient, wherein the at least one steroid hormone (progestogen) has a particle size distribution profile ranging from about one nanometer to about ten microns in the powder blend.

Description

[0001] Cross References to Related Applications

[0002] This application is a currently pending Continuation-In-Part application of U.S. Patent Application No. 13 / 021,950, filed February 7, 2011, and claims PCT International Patent Application No. The benefit of PCT / US11 / 23917 and US Provisional Patent Application No. 61 / 302,325, filed February 8, 2010, the entire contents of which are incorporated herein by reference. field of invention

[0003] Glucocorticoid insensitivity is a difficult problem to manage in diseases / conditions treated with glucocorticoids because of the lack of effective treatments. The invention particularly relates to inhalation formulations comprising progestins such as 17α-hydroxyprogesterone caproate (17-HPC); and for administration of progestins as glucocorticoid sensitizers to restore corticosteroid sensitivity or to reverse glucocorticoid Methods and kits for hormone insensitivity or for enhancing glucocorticoid sensitivity to treat one or more di...

Images